{"nctId":"NCT01896193","briefTitle":"Safety and Efficacy Study of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Genotype 1 and 3 Chronic HCV Infection","startDateStruct":{"date":"2013-06"},"conditions":["Hepatitis C"],"count":127,"armGroups":[{"label":"SOF+RBV 16 Weeks","type":"EXPERIMENTAL","interventionNames":["Drug: SOF","Drug: RBV"]},{"label":"SOF+RBV 24 Weeks","type":"EXPERIMENTAL","interventionNames":["Drug: SOF","Drug: RBV"]}],"interventions":[{"name":"SOF","otherNames":["Sovaldi®","PSI-7977","GS-7977"]},{"name":"RBV","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Confirmed chronic genotype 1 or 3 HCV infection\n* HCV treatment-naive\n* Individuals will have cirrhosis status assessment; liver biopsy may be required.\n* Screening laboratory values within predefined thresholds\n* Use of two effective contraception methods if female of childbearing potential or sexually active male\n\nExclusion Criteria:\n\n* Pregnant or nursing female or male with pregnant female partner\n* Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)\n* Contraindication to ribavirin therapy\n* Excessive alcohol ingestion as defined by protocol\n* History of solid organ transplantation\n* Current or prior history of clinical hepatic decompensation\n* History of clinically significant illness or any other medical disorder that may interfere with the individual's treatment, assessment, or compliance with the protocol","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12)","description":"SVR12 was defined as HCV RNA \\< the lower limit of quantitation (LLOQ; ie, 25 IU/mL) at 12 weeks after stopping study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null},{"groupId":"OG001","value":"76.5","spread":null},{"groupId":"OG002","value":"86.7","spread":null},{"groupId":"OG003","value":"90.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Incidence of Adverse Events Leading to Permanent Discontinuation of Study Drug(s)","description":"The percentage of participants permanently discontinuing any study drug due to an adverse event was summarized.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Sustained Virologic Response at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)","description":"SVR4 and SVR 24 were defined as HCV RNA \\< LLOQ at 4 and 24 weeks following the last dose of study drug, respectively.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.1","spread":null},{"groupId":"OG001","value":"76.5","spread":null},{"groupId":"OG002","value":"90.0","spread":null},{"groupId":"OG003","value":"90.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.9","spread":null},{"groupId":"OG001","value":"76.5","spread":null},{"groupId":"OG002","value":"86.7","spread":null},{"groupId":"OG003","value":"90.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Experiencing On-treatment Virologic Failure","description":"On-treatment virologic failure was defined as\n\n* Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \\< LLOQ while on treatment), or\n* Rebound (confirmed \\> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or\n* Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Experiencing Virologic Relapse","description":"Virologic relapse was defined as confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \\< LLOQ at last on-treatment visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null},{"groupId":"OG001","value":"23.5","spread":null},{"groupId":"OG002","value":"13.3","spread":null},{"groupId":"OG003","value":"9.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":62},"commonTop":["Headache","Asthenia","Respiratory tract infection viral","Fatigue","Insomnia"]}}}